Search

Eyewire News: The Podcast

Eyewire News: The Podcast

12.17.25

Update on Reproxalap PDUFA Timing

Aldeyra provides an update on the timing of its dry eye disease treatment candidate reproxalap; Ocular Therapeutix pursues an accelerated NDA pathway for wet AMD therapy Axpaxli; and companies with late-stage drug candidates announce FDA submission plans. Learn more about your ad choices. Visit megaphone.fm/adchoices

View full description +

MORE EPISODES

03.04.26

FDA Agrees to Review Phentolamine for Presbyopia

02.25.26

Zeiss Launches App to Improve Workflow

02.18.26

Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli

02.11.26

Study: Metformin May Lower AMD Progression

02.04.26

First Dual-Agent Eye Drop for Presbyopia Approved

01.28.26

FDA Approves Label Supplement for iDose TR

01.21.26

Rayner Launches New Phaco System

01.14.26

Moorfields Researchers Reveal Promising Treatment for Hypotony

Show More

Anterior 3D Cataract Cornea General Glaucoma Optometry Pediatric Refractive/LVC Residents & Fellows Retina Retina 3D